febuxostat

Summary

Summary: A thiazole derivative and inhibitor of XANTHINE OXIDASE that is used for the treatment of HYPERURICEMIA in patients with chronic GOUT.

Top Publications

  1. Deeks E. Lesinurad: A Review in Hyperuricaemia of Gout. Drugs Aging. 2017;34:401-410 pubmed publisher
    ..allopurinol in adults with gout inadequately responsive to allopurinol (CLEAR 1 and 2) and in combination with febuxostat in adults with tophaceous gout (CRYSTAL)...
  2. Lin Z, Zhang R, Fan C, Liang Y, Li L, Zhao L, et al. [Effect of febuxostat on epithelial-to-mesenchymal transition of kidney tubules, serum interleukin-6 and transforming growth factor ?(1) in hyperuricemic rats]. Zhonghua Nei Ke Za Zhi. 2017;56:363-367 pubmed publisher
    b>Objective: To observe the effect of febuxostat on epithelial-to-mesenchymal transition (EMT) of kidney tubules and the levels of serum IL-6 nad transforming growth factor (TGF)?(1) in hyperuricemic rats...
  3. Smelcerovic A, Tomovic K, Smelcerovic Z, Petronijevic Z, Kocic G, Tomasić T, et al. Xanthine oxidase inhibitors beyond allopurinol and febuxostat; an overview and selection of potential leads based on in silico calculated physico-chemical properties, predicted pharmacokinetics and toxicity. Eur J Med Chem. 2017;135:491-516 pubmed publisher
    ..Derivatives of imidazole, 1,3-thiazole and pyrimidine proved to be more potent than febuxostat while also displaying/possessing favorable predicted physico-chemical, pharmacokinetic and toxicological ..
  4. Singh J, Cleveland J. Comparative effectiveness of allopurinol versus febuxostat for preventing incident renal disease in older adults: an analysis of Medicare claims data. Ann Rheum Dis. 2017;76:1669-1678 pubmed publisher
    To assess the comparative effectiveness of allopurinol versus febuxostat for preventing incident renal disease in elderly...
  5. Horikoshi R, Akimoto T, Inoue M, Morishita Y, Kusano E. Febuxostat for hyperuricemia: experience with patients on chronic hemodialysis treatment. Clin Exp Nephrol. 2013;17:149-50 pubmed publisher
  6. Vargas Santos A, Neogi T. Management of Gout and Hyperuricemia in CKD. Am J Kidney Dis. 2017;70:422-439 pubmed publisher
    ..At present, asymptomatic hyperuricemia is not an indication for urate-lowering therapy, though emerging data may support a potential renoprotective effect. ..
  7. D Hayashi R, Yamaoka M, Nishizawa H, Fukuda S, Fujishima Y, Kimura T, et al. Multiple Gouty Tophi with Bone Erosion and Destruction: A Report of an Early-onset Case in an Obese Patient. Intern Med. 2017;56:1071-1077 pubmed publisher
    ..In this case, bone and Ga-67 scintigraphy were useful for detecting the location and magnitude of gouty tophi. ..
  8. Nanmoku K, Kurosawa A, Shinzato T, Shimizu T, Kimura T, Yagisawa T. Febuxostat for the Prevention of Recurrent 2,8-dihydroxyadenine Nephropathy due to Adenine Phosphoribosyltransferase Deficiency Following Kidney Transplantation. Intern Med. 2017;56:1387-1391 pubmed publisher
    ..After a genetic diagnosis, febuxostat treatment was started on postoperative day 7, with the dosage gradually increased to 80 mg/day until complete ..
  9. Dalbeth N, Jones G, Terkeltaub R, Khanna D, Kopicko J, Bhakta N, et al. Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial. Arthritis Rheumatol. 2017;69:1903-1913 pubmed publisher
    To investigate the efficacy and safety of lesinurad in combination with febuxostat in a 12-month phase III trial in patients with tophaceous gout. Patients with serum urate (UA) ?8.0 mg/dl (?6...
  10. Kishimoto K, Kobayashi R, Hori D, Sano H, Suzuki D, Kobayashi K. Febuxostat as a Prophylaxis for Tumor Lysis Syndrome in Children with Hematological Malignancies. Anticancer Res. 2017;37:5845-5849 pubmed
    The aim of the present study was to determine if febuxostat could prevent tumor lysis syndrome (TLS) in children who received induction chemotherapy for hematologic malignancies.

Detail Information

Publications11

  1. Deeks E. Lesinurad: A Review in Hyperuricaemia of Gout. Drugs Aging. 2017;34:401-410 pubmed publisher
    ..allopurinol in adults with gout inadequately responsive to allopurinol (CLEAR 1 and 2) and in combination with febuxostat in adults with tophaceous gout (CRYSTAL)...
  2. Lin Z, Zhang R, Fan C, Liang Y, Li L, Zhao L, et al. [Effect of febuxostat on epithelial-to-mesenchymal transition of kidney tubules, serum interleukin-6 and transforming growth factor ?(1) in hyperuricemic rats]. Zhonghua Nei Ke Za Zhi. 2017;56:363-367 pubmed publisher
    b>Objective: To observe the effect of febuxostat on epithelial-to-mesenchymal transition (EMT) of kidney tubules and the levels of serum IL-6 nad transforming growth factor (TGF)?(1) in hyperuricemic rats...
  3. Smelcerovic A, Tomovic K, Smelcerovic Z, Petronijevic Z, Kocic G, Tomasić T, et al. Xanthine oxidase inhibitors beyond allopurinol and febuxostat; an overview and selection of potential leads based on in silico calculated physico-chemical properties, predicted pharmacokinetics and toxicity. Eur J Med Chem. 2017;135:491-516 pubmed publisher
    ..Derivatives of imidazole, 1,3-thiazole and pyrimidine proved to be more potent than febuxostat while also displaying/possessing favorable predicted physico-chemical, pharmacokinetic and toxicological ..
  4. Singh J, Cleveland J. Comparative effectiveness of allopurinol versus febuxostat for preventing incident renal disease in older adults: an analysis of Medicare claims data. Ann Rheum Dis. 2017;76:1669-1678 pubmed publisher
    To assess the comparative effectiveness of allopurinol versus febuxostat for preventing incident renal disease in elderly...
  5. Horikoshi R, Akimoto T, Inoue M, Morishita Y, Kusano E. Febuxostat for hyperuricemia: experience with patients on chronic hemodialysis treatment. Clin Exp Nephrol. 2013;17:149-50 pubmed publisher
  6. Vargas Santos A, Neogi T. Management of Gout and Hyperuricemia in CKD. Am J Kidney Dis. 2017;70:422-439 pubmed publisher
    ..At present, asymptomatic hyperuricemia is not an indication for urate-lowering therapy, though emerging data may support a potential renoprotective effect. ..
  7. D Hayashi R, Yamaoka M, Nishizawa H, Fukuda S, Fujishima Y, Kimura T, et al. Multiple Gouty Tophi with Bone Erosion and Destruction: A Report of an Early-onset Case in an Obese Patient. Intern Med. 2017;56:1071-1077 pubmed publisher
    ..In this case, bone and Ga-67 scintigraphy were useful for detecting the location and magnitude of gouty tophi. ..
  8. Nanmoku K, Kurosawa A, Shinzato T, Shimizu T, Kimura T, Yagisawa T. Febuxostat for the Prevention of Recurrent 2,8-dihydroxyadenine Nephropathy due to Adenine Phosphoribosyltransferase Deficiency Following Kidney Transplantation. Intern Med. 2017;56:1387-1391 pubmed publisher
    ..After a genetic diagnosis, febuxostat treatment was started on postoperative day 7, with the dosage gradually increased to 80 mg/day until complete ..
  9. Dalbeth N, Jones G, Terkeltaub R, Khanna D, Kopicko J, Bhakta N, et al. Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial. Arthritis Rheumatol. 2017;69:1903-1913 pubmed publisher
    To investigate the efficacy and safety of lesinurad in combination with febuxostat in a 12-month phase III trial in patients with tophaceous gout. Patients with serum urate (UA) ?8.0 mg/dl (?6...
  10. Kishimoto K, Kobayashi R, Hori D, Sano H, Suzuki D, Kobayashi K. Febuxostat as a Prophylaxis for Tumor Lysis Syndrome in Children with Hematological Malignancies. Anticancer Res. 2017;37:5845-5849 pubmed
    The aim of the present study was to determine if febuxostat could prevent tumor lysis syndrome (TLS) in children who received induction chemotherapy for hematologic malignancies.
  11. Singh J. Facilitators and barriers to adherence to urate-lowering therapy in African-Americans with gout: a qualitative study. Arthritis Res Ther. 2014;16:R82 pubmed publisher
    ..Identification of facilitators and barriers to high ULT adherence in African-Americans with gout in this study lays the foundation for designing interventions to improve ULT adherence in racial minorities. ..